BDX Stock Analysis
NYQ · Healthcare · Medical Instruments & Supplies
$182.93
-0.90 (-0.49%)
BDX Interactive Price Chart & Trading Signals
BDX Stock Snapshot — Valuation, Risk & Technical Signals
BDX Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$49.83B
P/E Ratio
31.70
Forward P/E
13.76
PEG Ratio
1.11
P/B Ratio
2.04
EPS
$5.77
Dividend Yield
2.28%
52W Range
$127.59 – $193.07
Beta
0.28
Volume
0.5M
ROE
6.6%
Profit Margin
4.2%
Revenue Growth
5.4%
Gross Margin
46.9%
EV/EBITDA
10.81
Analyst Target
$195.67
The trailing price-to-earnings ratio stands at 31.7x. Forward P/E of 13.8x implies earnings expansion expected. Price-to-book is 2.04x. EV/EBITDA sits at 10.81x. Market capitalization is $49.83B. Revenue is growing at 5.4% on a trailing basis. Earnings are compressing at -31.4%. Profit margins are 4.2%. Return on equity is 6.6%. Beta of 0.28 indicates defensive profile.
Analyst Consensus
Recommendation
Buy
Low Target
$170.00
Mean Target
$195.67
High Target
$225.00
Based on 12 analysts
About BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
BDX Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
General investorWatch out for
Premium valuation, Earnings declineNon-zero inputs
4/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
Becton, Dickinson and Company (BDX) trades above our multi-model fair value estimate of $118.56 by approximately 35.2%. Trailing P/E: 31.7x. Profitability signals include profit margin of 4.2% and return on equity of 6.6%. Recent growth metrics show revenue growth of 5.4% and earnings growth of -31.4%. Risk profile: defensive beta of 0.28. Consensus: buy.
Valuation, Growth & Risk
Valuation
Overvalued
P/E 31.7x
Price is above what fundamentals suggest.
Growth
Expanding
Rev 5.4%
Revenue is outpacing the market.
Risk
Low
Beta 0.28
Movement is likely to track the broader market.
Valuation Snapshot
Becton, Dickinson and Company (BDX) trades above our multi-model fair value estimate of $118.56 by approximately 35.2%. The trailing price-to-earnings ratio stands at 31.7x. Forward P/E of 13.8x suggests earnings compression ahead. Price-to-sales is 2.2x. Price-to-book is 2.0x. EV/EBITDA sits at 10.8x. Market capitalization is $49.83B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 5.4% on a trailing basis. Earnings are compressing at -31.4%. Profit margins are 4.2%. Return on equity is 6.6%. Return on assets is 4.3%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 0.28 indicates defensive profile. Net debt position is $16.10B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $195.67 implies 7.0% upside. Target range spans $170.00 to $225.00. 12 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Investor Fit
Free cash flow yield of 5.4% is attractive for cash-flow-focused investors.
Takeaway: Match the stock's risk-reward profile with your own goals and time horizon. No single metric tells the whole story.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
BDX Overvalued
Becton, Dickinson and Company (BDX) trades above our multi-model fair value estimate of $118.56 by approximately 35.2%.
Frequently Asked Questions
ValuationIs BDX stock overvalued right now?
ValuationWhat is BDX fair value based on current fundamentals?
RiskHow risky is BDX compared with other stocks?
GrowthIs BDX still growing?
AnalystWhat do analysts think about BDX?
DividendDoes BDX pay a dividend?
CatalystWhat could change the investment case for BDX?
Related Stocks
About the Author
Phasakorn Traklang (Peach) — Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.